Sangamo Therapeutics filed for Chapter 11 bankruptcy protection and agreed to asset-sale agreements that would transfer major technology platforms and a subset of programs. In the filings, Eli Lilly agreed to acquire Sangamo’s capsid delivery platform, ZFN platform, modular integrase platform, and the ST-506 prion disease program, while Astellas agreed to take Sangamo’s Fabry disease program, isaralgagene civaparvovec (ST-920). The agreements are structured with Lilly and Astellas acting as stalking-horse bidders in an upcoming bankruptcy court auction. Sangamo said the deals do not include certain other programs, including clinical-stage ST-503 and giroctocogene fitelparvovec (hemophilia A), which are expected to remain available for interested bidders at auction. The outcome highlights continuing consolidation pressure on gene-editing and gene-delivery companies facing capital constraints, particularly after years of platform investment without near-term, diversified commercialization. The next step for stakeholders will be how the auction determines the final breadth of asset transfers and whether remaining programs find suitors.